57 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
alternate dosage forms for IkT-001Pro relative to imatinib mesylate as the primary mitigation strategy and will provide a justification of the dosage forms … ” from the brain. A “plaque”-focused treatment strategy has failed to alter the course of Parkinson’s disease in two Phase 2 trials that reported results
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
30 Apr 24
Regulation FD Disclosure
8:17am
& Strategy Inhibikase.com : IKT 6
THE MARKET: DISEASE-MODIFICATION WILL TRANSFORM TREATMENT PARADIGM 1 Parkinson’s disease and MSA in the U.S
424B5
t4lh 395wksyw03nms
1 Feb 24
Prospectus supplement for primary offering
4:49pm
424B3
yxdoax89ni8
4 Apr 23
Prospectus supplement
4:57pm
POS AM
376bbk46e gs
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm